Health Care

Exelixis Inc. gains institutional backing and rides a projected rise in rhabdomyosarcoma market, with its Cabozantinib partnership poised to boost growth.

UniQure’s share plunge after the FDA flagged AMT‑130 data highlights regulatory risk, legal investigations, and a bearish market—find out why investors are concerned.

Verrica Pharmaceuticals (VRCA) sees fresh institutional backing as insider buying by John Kirby and Caligan Partners LP fuels optimism for its dermatology pipeline and potential Phase 2 acceleration.

Eurofins Scientific SE: Regulatory updates, food‑safety growth, and strong fundamentals signal solid upside for investors in a booming testing market.

Akebia Therapeutics, a Cambridge‑based biotech, focuses on HIF‑based kidney disease drugs, blending research breakthroughs with investor‑friendly insights.

Profound Medical Corp: Revolutionizing localized prostate cancer treatment with cutting‑edge tech, strong market recovery, and a global focus on innovation.

Arcutis Biotherapeutics: $3.79B Nasdaq biopharma focused on groundbreaking immune‑mediated therapies, strong R&D investment, and a resilient market trajectory.

WuXi AppTec shares fell 3% amid a broader market retreat as U.S. security concerns and a €3 m contract with a military‑linked firm raise investor risk‑wary speculation about its CRO growth prospects.

Abivax SA: How a French biotech’s anti‑viral pipeline is riding a health‑care rotation and what clinical milestones could spark its next growth surge.

Perspectum Group PLC: AI‑driven digital diagnostics & personalized treatment tools for metabolic diseases and cancer—boosting early detection, clinical workflows, and patient outcomes worldwide.